The present disclosure includes compositions and methods for treating cardiovascular disease (CVD) (e.g., cholesterol related disorders, or diseases caused or characterized by increased levels of plasma triglycerides, plasma cholesterol, or serum C-reactive protein), or symptoms thereof. The disclosure also includes compositions and methods for lowering plasma triglycerides in a subject, lowering plasma cholesterol levels in a subject, and lowering serum C-reactive protein levels in a subject.